Long-term outcomes of kidney transplantation in 2332 patients under cyclosporine A
Sen-lin HUANG,Li-xin YU,Wen-feng DENG,Yun MIAO,Shao-jie FU,Jian XU,Chuan-fu DU,Yi-bin WANG,Gui-rong YE
DOI: https://doi.org/10.13820/j.cnki.gdyx.20160413.007
2016-01-01
Abstract:Objective To investigate the long-term efficacy and safety for cyclosporine A ( CsA) in renal trans-plant recipients. Methods A total of 2332 kidney recipients were divided into three groups (1) children ( <18 years of age)(GI, n=27);(2) adults (18 to 60 ys) (GII, n=2 086); and (3) elderly recipients ( >60 ys) (GIII, n=219);Information was obtained on acute rejection (AR), chronic rejection (CR), side effect, patient and graft survival at 1, 3, 5 and 10 years. Data were compared among the three groups, with GII as the control group. Results At a mean follow up time of 87. 2 months, incidences of AR/CR for all patients and within each group were 17. 0%/13. 2%, 40. 7%/29. 6% (GI), 17. 1%/13. 4%(GII) and 13. 2%/9. 1%(GIII), respectively. Patient/graft survival at 1, 3, 5 and 10 years were 97. 0%/96. 7%, 93. 2%/86. 2%, 88. 4%/82. 7% and 83. 4%/65. 4% for all recipients; 96. 3%/96. 3%, 92. 6%/85. 2%, 88. 9%/81. 5% and 81. 5%/63. 0% for GI; 97. 5%/96. 9%, 93. 4%/86. 1%, 88. 9%/82. 8% and 84. 0%/65. 3% for GII and 94. 5%/94. 1%, 91. 8%/87. 2%, 83. 6%/82. 2% and 78. 1%/66. 2% for GI-II, respectively. Compared with GII, GI had higher AR and CR incidences (P=0. 003, P=0. 022), however, patient/graft survivals were similar (P=0. 34, P=0. 08). Compared with GII, CR incidence and patient survival were lower for GIII (P=0. 035, P=0. 009), but AR incidence and graft survival were similar between the two groups (P=0. 074, P=0. 28). The major long - term side effects associated with CsA - based immunosuppression include hepatoxicity (16. 5%), nephrotoxicity (17. 7%), hyperlipidemia (17. 4%), hypertension (32. 8%), impaired glucose metabolism (13. 2%), gingival hyperplasia (35. 7%) and hirsutism (24. 1%), etc. Most adverse effects were alleviated or elimina-ted by dose minimization of CsA, combination with other immunosuppressant agents and symptomatic treatments. Conclu-sion CsA is an effective immunosuppressive agent that is safe for long-term treatment in adult, pediatric and elderly pa-tients as well. Good HLA matching, precise adjustment for CsA dosage and combination with other immunosuppressant a-gents allow for a reduction of CsA dosing and therefore lead to a reduction of CsA-related toxic effects.